植物半胱氨酸蛋白酶抑制剂CsinCPI-2减少破骨细胞生成及牙槽骨丢失
本研究探讨橙树来源的新型半胱氨酸肽酶抑制剂CsinCPI-2对牙周炎的作用。在小鼠结扎诱导牙周炎模型中,CsinCPI-2(0.8 µg/g体重)显著减少结缔组织炎症细胞浸润、防止牙槽骨量(BV/TV)丢失,并减少TRAP阳性多核细胞。体外实验显示CsinCPI-2浓度依赖性抑制RANKL诱导的破骨细胞形成,且无细胞毒性,并下调Acp5、Calcr、Ctsk及Nfatc1表达。
要点
- CsinCPI-2可减少牙周炎小鼠模型中的炎症细胞浸润和牙槽骨丢失。
- CsinCPI-2直接抑制RANKL诱导的破骨细胞分化,且无细胞毒性。
- CsinCPI-2可能成为牙周炎治疗中靶向骨吸收细胞的潜在策略。
核心结论
- CsinCPI-2通过控制炎症过程并直接作用于破骨细胞生成,防止牙周炎诱导的骨丢失,提示其在牙周炎治疗策略中的潜力。
研究设计与样本
- 采用小鼠结扎诱导牙周炎模型,给予CsinCPI-2(0.8 µg/g体重)治疗。
- 体外使用小鼠骨髓巨噬细胞培养,观察CsinCPI-2对RANKL诱导破骨细胞形成的影响。
主要发现
- CsinCPI-2治疗显著减少结缔组织炎症细胞浸润,防止牙周炎导致的牙槽骨量(BV/TV)丢失,并减少TRAP阳性多核细胞数量。
- CsinCPI-2显著下调表达CD3、CD45、MAC387和IL-1β的炎症细胞数量。
- 体外CsinCPI-2浓度依赖性抑制RANKL诱导的TRAP+多核破骨细胞形成,且MTT实验显示该效应非细胞毒性所致。
- CsinCPI-2抑制RANKL诱导的Acp5、Calcr、Ctsk mRNA表达以及Nfatc1的上调。
临床怎么用
- CsinCPI-2可能作为牙周炎辅助治疗药物,通过抑制炎症和破骨细胞生成减少牙槽骨丢失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Periodontal disease (PD) is a polymicrobial chronic inflammatory condition of the supporting tissues around the teeth, leading to the destruction of surrounding connective tissue. During the progression of PD, osteoclasts play a crucial role in the resorption of alveolar bone that eventually leads to the loss of teeth if the PD is left untreated. Therefore, the development of antiresorptive therapies targeting bone-resorbing cells will significantly benefit the treatment of PD. Here, we demonstrate the inhibitory effect of CsinCPI-2, a novel cysteine peptidase inhibitor from the orange tree, on periodontitis-induced inflammation, alveolar bone loss, and osteoclast differentiation. Using the ligature-induced periodontitis model in mice, we show that treatment with CsinCPI-2 (0.8 µg/g of body weight) significantly reduced inflammatory cell infiltrate in the connective tissue and prevented the loss of alveolar bone mass (BV/TV) caused by PD, effects associated with diminished numbers of TRAP-positive multinucleated cells. Furthermore, CsinCPI-2 significantly downregulated the numbers of inflammatory cells expressing CD3, CD45, MAC387, and IL-1β. In vitro, CsinCPI-2 inhibited RANKL-induced TRAP+ multinucleated osteoclast formation in mouse bone marrow macrophage cultures in a concentration-dependent manner. This effect was not due to cytotoxicity, as demonstrated by the MTT assay. CsinCPI-2 inhibited RANKL-induced mRNA expression of Acp5, Calcr, and Ctsk, as well as the RANKL-induced upregulation of Nfatc1, a crucial transcription factor for osteoclast differentiation. Based on our findings, CsinCPI-2 prevents bone loss induced by PD by controlling the inflammatory process and acting directly on osteoclastogenesis, suggesting an interesting potential for CsinCPI-2 in the strategy for PD treatment.
引用
- Da Ponte Leguizamón N, de Molon RS, Coletto-Nunes G, et al. Phytocystatin CsinCPI-2 Reduces Osteoclastogenesis and Alveolar Bone Loss. J Dent Res. 2021. PMID: 34328027. doi:10.1177/00220345211027811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。